Literature DB >> 29101030

The alpha2-adrenoreceptor agonist dexmedetomidine protects against lipopolysaccharide-induced apoptosis via inhibition of gap junctions in lung fibroblasts.

Yuan Zhang1, Xiaoming Tan2, Lianfang Xue3.   

Abstract

The α2-adrenoceptor inducer dexmedetomidine protects against acute lung injury (ALI), but the mechanism of this effect is largely unknown. The present study investigated the effect of dexmedetomidine on apoptosis induced by lipopolysaccharide (LPS) and the relationship between this effect and gap junction intercellular communication in human lung fibroblast cell line. Flow cytometry was used to detect apoptosis induced by LPS. Parachute dye coupling assay was used to measure gap junction function, and western blot analysis was used to determine the expression levels of connexin43 (Cx43). The results revealed that exposure of human lung fibroblast cell line to LPS for 24 h increased the apoptosis, and pretreatment of dexmedetomidine and 18α-GA significantly reduced LPS-induced apoptosis. Dexmedetomidine exposure for 1 h inhibited gap junction function mainly via a decrease in Cx43 protein levels in human lung fibroblast cell line. These results demonstrated that the inhibition of gap junction intercellular communication by dexmedetomidine affected the LPS-induced apoptosis through inhibition of gap junction function by reducing Cx43 protein levels. The present study provides evidence of a novel mechanism underlying the effects of analgesics in counteracting ALI.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Dexmedetomidine; Gap junction; connexin43

Mesh:

Substances:

Year:  2017        PMID: 29101030     DOI: 10.1016/j.bbrc.2017.10.162

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  A modified parachute assay for assessment of gap junction intercellular communication in placental trophoblast cells.

Authors:  Jeremy Gingrich; Yong Pu; Almudena Veiga-Lopez
Journal:  Toxicol Mech Methods       Date:  2021-03-30       Impact factor: 4.019

2.  Dexmedetomidine Attenuates Monocyte-Endothelial Adherence via Inhibiting Connexin43 on Vascular Endothelial Cells.

Authors:  Yunfei Chai; Runying Yu; Yong Liu; Sheng Wang; Dongdong Yuan; Jimei Chen
Journal:  Mediators Inflamm       Date:  2020-02-10       Impact factor: 4.711

3.  Perioperative Dexmedetomidine attenuates brain ischemia reperfusion injury possibly via up-regulation of astrocyte Connexin 43.

Authors:  Xiaoyang Zheng; Xiaoying Cai; Fang Ye; Ying Li; Qin Wang; Zhiyi Zuo; Wenqi Huang; Zhongxing Wang
Journal:  BMC Anesthesiol       Date:  2020-12-07       Impact factor: 2.217

Review 4.  The Role of Connexin 43 in Lung Disease.

Authors:  Julie A Swartzendruber; Bruce J Nicholson; Ashlesh K Murthy
Journal:  Life (Basel)       Date:  2020-12-19

5.  Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway.

Authors:  Haibin Cui; Qian Zhang
Journal:  J Anesth       Date:  2021-04-05       Impact factor: 2.078

6.  Dexmedetomidine Alleviates Lipopolysaccharide-Induced Hippocampal Neuronal Apoptosis via Inhibiting the p38 MAPK/c-Myc/CLIC4 Signaling Pathway in Rats.

Authors:  Yongping Chen; Lin Li; Jiuyan Zhang; Hailin Cui; Jiucheng Wang; Chuqiao Wang; Mingxian Shi; Honggang Fan
Journal:  Mol Neurobiol       Date:  2021-08-07       Impact factor: 5.590

7.  Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis through Inhibition of the ROS/JNK Signaling Pathway.

Authors:  Yongping Chen; Xiujing Feng; Xueyuan Hu; Jichen Sha; Bei Li; Huayun Zhang; Honggang Fan
Journal:  Oxid Med Cell Longev       Date:  2018-09-03       Impact factor: 6.543

8.  Dexmedetomidine alleviates insulin resistance in hepatocytes by reducing endoplasmic reticulum stress.

Authors:  Fanfan Liu; Shaojun Zhu; Lifeng Ni; Ling'er Huang; Kuirong Wang; Yanfeng Zhou
Journal:  Endocrine       Date:  2019-11-02       Impact factor: 3.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.